Back

EHA 2021 - Annual Congress of the European Hematology Association (Virtual Meeting)

Jun 09 - Jun 17, 2021 | ViennaAustria

LARVOL is not affiliated with Annual Congress of the European Hematology Association (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners

Showing 364 abstracts linked to Trials

[VIRTUAL] FIRST INTERIM ANALYSIS OF ALPINE STUDY: RESULTS OF A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

  • Late-Breaking
15 Twitter Reactions

[VIRTUAL] OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY

  • Late-Breaking
12 Twitter Reactions

[VIRTUAL] FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY

  • Late-Breaking
8 Twitter Reactions

[VIRTUAL] SAFETY AND EFFICACY OF CD37-TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND OTHER NON-HODGKIN’S B-CELL LYMPHOMAS – A PHASE 2 STUDY

  • Late-Breaking, Oral
3 Twitter Reactions